Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.

Wan QianyiXu MeiZhao RuiWang YongWu YutaoShen XiaodingXiao Ting Wu

Published in: Journal of cancer research and clinical oncology (2021)

Delayed postoperative adjuvant imatinib for over 4 months in patients with high risk of recurrence of GIST may lead to worse RFS, and longer treatment with shorter delay has best results.

Keyphrases

early stage
chronic myeloid leukemia
minimally invasive
free survival
coronary artery bypass
patients undergoing
combination therapy
percutaneous coronary intervention